Summary
Guardant Health, Inc. (GH) filed its quarterly report for the period ending September 30, 2018. This filing highlights the company's ongoing efforts in the precision oncology market, primarily driven by its Guardant360 test. The report details significant risks and challenges, including the company's continued history of incurring net losses, the dependence on commercial market acceptance of its products, and the complexities and uncertainties surrounding reimbursement from third-party payers, particularly Medicare. Key operational aspects discussed involve the company's reliance on its single laboratory facility and the potential impact of disruptions. Furthermore, the report emphasizes the extensive regulatory landscape governing clinical laboratory testing, including potential shifts in FDA enforcement discretion regarding Laboratory Developed Tests (LDTs), and the ongoing patent litigation with competitors such as Foundation Medicine, Inc. and Personal Genome Diagnostics, Inc. Investors should note the company's recent Initial Public Offering (IPO) in October 2018, which provided a substantial capital infusion.
Financial Highlights
49 data points| Revenue | $21.69M |
| R&D Expenses | $14.25M |
| Operating Expenses | $45.90M |
| Operating Income | -$24.20M |
| Interest Expense | $304K |
| Net Income | -$23.51M |
| EPS (Basic) | $-1.94 |
| Shares Outstanding (Basic) | 12.58M |
Key Highlights
- 1Guardant Health continues to generate significant net losses, with an accumulated deficit of $255.4 million as of September 30, 2018, underscoring the need for future revenue growth to achieve profitability.
- 2The company is heavily reliant on its Guardant360 test, which accounts for the substantial majority of its revenue, making its success contingent on continued market adoption and acceptance.
- 3Significant revenue generation depends on favorable coverage and reimbursement decisions from third-party payers, including Medicare, which represented approximately 38% of U.S. test volume in 2017 and the first nine months of 2018. Reimbursement challenges and potential retroactive adjustments from payers pose a material risk.
- 4The company is involved in ongoing patent litigation, having filed lawsuits alleging infringement against Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc., highlighting the competitive and litigious nature of the genomic testing market.
- 5The regulatory environment for clinical laboratory testing is complex and evolving. The company notes the FDA's potential changes to its enforcement discretion policy for Laboratory Developed Tests (LDTs), which could impose significant new regulatory requirements.
- 6Guardant Health recently completed its Initial Public Offering (IPO) in October 2018, raising approximately $254.0 million in net proceeds, which is expected to fund operations and growth initiatives.
- 7The company operates from a single laboratory facility, making it vulnerable to disruptions from natural disasters, equipment failure, or other unforeseen events that could significantly impact operations.